ERK Inhibitor JSI-1187 in Advanced Solid Tumors
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- JS InnoPharm, LLC
- Target Recruit Count
- 60
- Registration Number
- NCT06239623
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations
- First Posted Date
- 2020-06-05
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- JS InnoPharm, LLC
- Target Recruit Count
- 71
- Registration Number
- NCT04418167
- Locations
- 🇺🇸
University of Arizona Comprehensive Cancer Center, Tucson, Arizona, United States
🇺🇸Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
© Copyright 2024. All Rights Reserved by MedPath